David O Nauheim1, Hannah Hackbart1, Emily Papai1, David Moskal1, Charles J Yeo1, Harish Lavu1, Avinoam Nevler2,3. 1. Department of Surgery, Biliary and Related Cancer Center, Thomas Jefferson University, Jefferson PancreasPhiladelphia, PA, USA. 2. Department of Surgery, Biliary and Related Cancer Center, Thomas Jefferson University, Jefferson PancreasPhiladelphia, PA, USA. Avinoam.Nevler@jefferson.edu. 3. Pancreatic Cancer Research Lab, Department of Surgery, Thomas Jefferson University, 1025 Walnut Street, Curtis Building, Suite 618, Philadelphia, PA, 19107, USA. Avinoam.Nevler@jefferson.edu.
Abstract
PURPOSE: Sarcopenia is common in pancreatic cancer patients. Considering the growing adoption of standardized protocols for enhanced recovery after surgery (ERAS), we examined the clinical impact of sarcopenia in pancreaticoduodenectomy (PD) patients in a 5-day accelerated ERAS program, termed the Whipple Accelerated Recovery Pathway. METHODS: A retrospective review was conducted of patients undergoing PD from 2017 through 2020 on the ERAS pathway. Preoperative computerized tomographic scans taken within 45 days before surgery were analyzed to determine psoas muscle cross-sectional area (PMA) at the third lumbar vertebral body. Sarcopenia was defined as the lowest quartile of PMA respective to gender. Outcome measures were compared between patients with or without sarcopenia. RESULTS: In this 333-patient cohort, 252 (75.7%) patients had final pathology revealing pancreatic or periampullary cancer. The median age was 66.7 years (16.4-88.4 years) with a 161:172 male to female ratio. Sarcopenia correlated with delayed tolerance of oral intake (OR 2.2; 95%CI 1.1-4.3, P = 0.03), increased complication rates (OR 4.3; 95%CI 2.2-8.5, P < 0.01), and longer hospital length of stay (LOS) (P < 0.05). Preoperative albumin levels, BMI, and history of pancreatitis were also found to correlate with LOS (P < 0.05). Multivariate regression analysis found low PMA, BMI, and male gender to be independent predictors of increased LOS (P < 0.05). CONCLUSION: Sarcopenia correlated with increased LOS and postoperative complications in ERAS patients after PD. Sarcopenia can be used to predict poor candidates for ERAS protocols who may require an alternative recovery protocol, promoting a clinical tier-based approach to ERAS for pancreatic surgery.
PURPOSE: Sarcopenia is common in pancreatic cancer patients. Considering the growing adoption of standardized protocols for enhanced recovery after surgery (ERAS), we examined the clinical impact of sarcopenia in pancreaticoduodenectomy (PD) patients in a 5-day accelerated ERAS program, termed the Whipple Accelerated Recovery Pathway. METHODS: A retrospective review was conducted of patients undergoing PD from 2017 through 2020 on the ERAS pathway. Preoperative computerized tomographic scans taken within 45 days before surgery were analyzed to determine psoas muscle cross-sectional area (PMA) at the third lumbar vertebral body. Sarcopenia was defined as the lowest quartile of PMA respective to gender. Outcome measures were compared between patients with or without sarcopenia. RESULTS: In this 333-patient cohort, 252 (75.7%) patients had final pathology revealing pancreatic or periampullary cancer. The median age was 66.7 years (16.4-88.4 years) with a 161:172 male to female ratio. Sarcopenia correlated with delayed tolerance of oral intake (OR 2.2; 95%CI 1.1-4.3, P = 0.03), increased complication rates (OR 4.3; 95%CI 2.2-8.5, P < 0.01), and longer hospital length of stay (LOS) (P < 0.05). Preoperative albumin levels, BMI, and history of pancreatitis were also found to correlate with LOS (P < 0.05). Multivariate regression analysis found low PMA, BMI, and male gender to be independent predictors of increased LOS (P < 0.05). CONCLUSION: Sarcopenia correlated with increased LOS and postoperative complications in ERAS patients after PD. Sarcopenia can be used to predict poor candidates for ERAS protocols who may require an alternative recovery protocol, promoting a clinical tier-based approach to ERAS for pancreatic surgery.
Authors: Kristoffer Lassen; Marielle M E Coolsen; Karem Slim; Francesco Carli; José E de Aguilar-Nascimento; Markus Schäfer; Rowan W Parks; Kenneth C H Fearon; Dileep N Lobo; Nicolas Demartines; Marco Braga; Olle Ljungqvist; Cornelis H C Dejong Journal: Clin Nutr Date: 2012-09-26 Impact factor: 7.324
Authors: Daniel Ansari; Bobby Tingstedt; Bodil Andersson; Fredrik Holmquist; Christian Sturesson; Caroline Williamsson; Agata Sasor; David Borg; Monika Bauden; Roland Andersson Journal: Future Oncol Date: 2016-06-01 Impact factor: 3.404
Authors: Emmanuel Melloul; Kristoffer Lassen; Didier Roulin; Fabian Grass; Julie Perinel; Mustapha Adham; Erik Björn Wellge; Filipe Kunzler; Marc G Besselink; Horacio Asbun; Michael J Scott; Cornelis H C Dejong; Dionisos Vrochides; Thomas Aloia; Jakob R Izbicki; Nicolas Demartines Journal: World J Surg Date: 2020-07 Impact factor: 3.352
Authors: H Furukawa; S Okada; H Saisho; J Ariyama; E Karasawa; A Nakaizumi; S Nakazawa; K Murakami; T Kakizoe Journal: Cancer Date: 1996-09-01 Impact factor: 6.860
Authors: Khe T C Tran; Hans G Smeenk; Casper H J van Eijck; Geert Kazemier; Wim C Hop; Jan Willem G Greve; Onno T Terpstra; Jan A Zijlstra; Piet Klinkert; Hans Jeekel Journal: Ann Surg Date: 2004-11 Impact factor: 12.969
Authors: Harish Lavu; Neal S McCall; Jordan M Winter; Richard A Burkhart; Michael Pucci; Benjamin E Leiby; Theresa P Yeo; Shawnna Cannaday; Charles J Yeo Journal: J Am Coll Surg Date: 2019-01-17 Impact factor: 6.113
Authors: Andrew McGuigan; Paul Kelly; Richard C Turkington; Claire Jones; Helen G Coleman; R Stephen McCain Journal: World J Gastroenterol Date: 2018-11-21 Impact factor: 5.742